{
    "organizations": [],
    "uuid": "1a951d0d6e0cdac01955782695af9040748282cb",
    "author": "",
    "url": "https://www.reuters.com/article/brief-sangamo-announces-uk-authorization/brief-sangamo-announces-u-k-authorization-of-clinical-trial-evaluating-zinc-finger-nuclease-idUSASB0C7ZD",
    "ord_in_thread": 0,
    "title": "BRIEF-Sangamo Announces U.K. Authorization Of Clinical Trial Evaluating Zinc Finger Nuclease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 40 PM / in 9 minutes BRIEF-Sangamo Announces U.K. Authorization Of Clinical Trial Evaluating Zinc Finger Nuclease Reuters Staff 1 Min Read Feb 28 (Reuters) - Sangamo Therapeutics Inc: * SANGAMO ANNOUNCES U.K. AUTHORIZATION OF CLINICAL TRIAL EVALUATING ZINC FINGER NUCLEASE IN VIVO GENOME EDITING TREATMENT FOR HEMOPHILIA B * SANGAMO THERAPEUTICS INC - EXPECTS TO INITIATE SITES IN U.K. LATER THIS YEAR FOR SB-FIX PHASE 1/2 CLINICAL TRIAL​ * SANGAMO THERAPEUTICS INC - ‍EXPECTS TO FILE ADDITIONAL CTAS FOR SB-318 & SB-913 IN VIVO GENOME EDITING TREATMENTS FOR MPS I AND MPS II, RESPECTIVELY​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)",
    "published": "2018-02-28T14:38:00.000+02:00",
    "crawled": "2018-02-28T15:04:29.013+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "announces",
        "authorization",
        "clinical",
        "trial",
        "evaluating",
        "zinc",
        "finger",
        "nuclease",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "sangamo",
        "therapeutic",
        "inc",
        "sangamo",
        "announces",
        "authorization",
        "clinical",
        "trial",
        "evaluating",
        "zinc",
        "finger",
        "nuclease",
        "vivo",
        "genome",
        "editing",
        "treatment",
        "hemophilia",
        "b",
        "sangamo",
        "therapeutic",
        "inc",
        "expects",
        "initiate",
        "site",
        "later",
        "year",
        "phase",
        "clinical",
        "sangamo",
        "therapeutic",
        "inc",
        "file",
        "additional",
        "ctas",
        "vivo",
        "genome",
        "editing",
        "treatment",
        "mp",
        "mp",
        "ii",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}